Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | June 06, 2023 | June 08, 2023 |
| Rainier Acquisition CorpRNAQ · Entity 527 | Director | August 26, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2033-06-06 | Direct | 38,700 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 38,700 · Balance 38,700 F1: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.
Rainier Acquisition Corp
Report date August 26, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Clene Inc.
Report date July 17, 2026 · Filed August 06, 2026
Section 16 reporting ended · disclosed 2026-08-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common Stock (Tranche B, $30.00 strike)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2030-06-16 | IndirectBy SymBiosis II LLC | 0 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Other · Disposed 375,000 · Balance 0 F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2: Currently exercisable |
| Common Stock Purchase Warrant ($4.82 strike)SEC Table II · derivative / convertible security · Conversion / exercise price $4.82 · Expires 2029-09-30 | IndirectBy SymBiosis II LLC | 0 |
Reported balance
After 2026-07-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-17 · Other · Disposed 424,358 · Balance 0 F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2: Currently exercisable |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred.
F2: Currently exercisable
F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received.
Tessera Defense & Homeland Security Inc.
Report date October 17, 2022 · Filed November 14, 2022
Section 16 reporting ended · disclosed 2022-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy SymBiosis, LLC | 2,997,025 |
Last balance in matching sequence
After 2022-11-04 transaction · row 15
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
15 source rowsRow 1 · 2022-10-17 · Sale · Disposed 8,098 · Balance 3,063,882 F1: The shares are directly held by SymBiosis, LLC. Row 2 · 2022-10-18 · Sale · Disposed 15,300 · Balance 3,048,582 F1: The shares are directly held by SymBiosis, LLC. Row 3 · 2022-10-19 · Sale · Disposed 4,501 · Balance 3,044,081 F1: The shares are directly held by SymBiosis, LLC. Row 4 · 2022-10-20 · Sale · Disposed 6,636 · Balance 3,037,445 F1: The shares are directly held by SymBiosis, LLC. Row 5 · 2022-10-21 · Sale · Disposed 5,400 · Balance 3,032,045 F1: The shares are directly held by SymBiosis, LLC. Row 6 · 2022-10-24 · Sale · Disposed 5,900 · Balance 3,026,145 F1: The shares are directly held by SymBiosis, LLC. Row 7 · 2022-10-25 · Sale · Disposed 3,072 · Balance 3,023,073 F1: The shares are directly held by SymBiosis, LLC. Row 8 · 2022-10-26 · Sale · Disposed 12,500 · Balance 3,010,573 F1: The shares are directly held by SymBiosis, LLC. Row 9 · 2022-10-27 · Sale · Disposed 1,505 · Balance 3,009,068 F1: The shares are directly held by SymBiosis, LLC. Row 10 · 2022-10-28 · Sale · Disposed 1,526 · Balance 3,007,542 F1: The shares are directly held by SymBiosis, LLC. Row 11 · 2022-10-31 · Sale · Disposed 3,300 · Balance 3,004,242 F1: The shares are directly held by SymBiosis, LLC. Row 12 · 2022-11-01 · Sale · Disposed 1,300 · Balance 3,002,942 F1: The shares are directly held by SymBiosis, LLC. Row 13 · 2022-11-02 · Sale · Disposed 2,416 · Balance 3,000,526 F1: The shares are directly held by SymBiosis, LLC. Row 14 · 2022-11-03 · Sale · Disposed 2,000 · Balance 2,998,526 F1: The shares are directly held by SymBiosis, LLC. Row 15 · 2022-11-04 · Sale · Disposed 1,501 · Balance 2,997,025 F1: The shares are directly held by SymBiosis, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are directly held by SymBiosis, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2021 Filed Apr 30, 2021 21:02 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 45,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003053 · primarydocument.xml · derivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-03-31 F1 · shares: This option was granted on April 30, 2021 as an option for 45,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $9.00 per share. The options vest in 36 equal installments of Common Stock on the last day of each calendar month, beginning May 31, 2021, until such shares are fully vested. F1 · derivative.exercise_date: This option was granted on April 30, 2021 as an option for 45,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $9.00 per share. The options vest in 36 equal installments of Common Stock on the last day of each calendar month, beginning May 31, 2021, until such shares are fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.